{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:38:13Z","timestamp":1792442293042,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Temocillin is a carbapenem-sparing \u03b2-lactam antibiotic used to treat infections caused by third-generation cephalosporin-resistant (3GC-R) Enterobacterales, although its use is not universally recommended. The aim of this study was to compare the efficacy of temocillin with that of other parenteral beta-lactams in the treatment of febrile urinary tract infections (UTIs) caused by 3GC-R Enterobacterales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We conducted a multicentre, retrospective, propensity score\u2013matched cohort study including patients treated between January 2017 and December 2021. Patients who received temocillin were matched 1:1 with patients who received carbapenems, cefepime or piperacillin\/tazobactam. The primary outcome was early clinical failure, defined as a composite of persistent symptoms leading to a switch in antibiotics or death within 10\u2005days after treatment completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 180 patients were included, with a high percentage of complicated UTIs (89%) but a low percentage of severe infections (21%). Early clinical failure occurred in 12% of patients overall, with no significant difference between the temocillin group (9%) and the comparator group (14%) (OR 0.58, 95% CI [0.23\u20131.48], P =\u200a0.26). The rates of late clinical failure, late microbiological failure and all-cause mortality within 3\u2005months were similar between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, compared with other beta-lactams, temocillin was not associated with an increased risk of early clinical failure in the treatment of 3GC-R Enterobacterales UTIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf370","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:37:52Z","timestamp":1758022672000},"page":"3329-3334","source":"Crossref","is-referenced-by-count":2,"title":["Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study"],"prefix":"10.1093","volume":"80","author":[{"given":"Jeanne","family":"Iachkine","sequence":"first","affiliation":[{"name":"Department of Medical Critical Care, CHU de Caen , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5695","authenticated-orcid":false,"given":"K\u00e9vin","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, Universit\u00e9 de Rouen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311; CHU Rouen, Department of Infectious Diseases , Rouen F-76000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Marlat","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, Universit\u00e9 de Rouen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311; CHU Rouen, Department of Infectious Diseases , Rouen F-76000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Briant","sequence":"additional","affiliation":[{"name":"CHU de Caen, Biostatistic and Clinical Research Unit , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Caron","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, Universit\u00e9 de Rouen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311; CHU Rouen, Department of Infectious Diseases , Rouen F-76000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Isnard","sequence":"additional","affiliation":[{"name":"Microbiology Department, CHU de Caen , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]},{"name":"Univ Caen Normandie, Universit\u00e9 de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Verdon","sequence":"additional","affiliation":[{"name":"Univ Caen Normandie, Universit\u00e9 de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, Caen F-14000 ,","place":["France"]},{"name":"Department of Infectious Diseases, CHU de Caen , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-5590","authenticated-orcid":false,"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[{"name":"CHU de Caen, Biostatistic and Clinical Research Unit , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]},{"name":"Department of Infectious Diseases, CHU de Caen , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Baldolli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, CHU de Caen , Avenue de la C\u00f4te de Nacre, Caen F-14000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025120206223948900_dkaf370-B1","volume-title":"Antimicrobial Resistance Surveillance in Europe 2022\u20132020 Data","author":"WHO Regional Office for Europe\/European Centre for Disease Prevention and Control","year":"2022"},{"key":"2025120206223948900_dkaf370-B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2025120206223948900_dkaf370-B3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003495-198500295-00050","article-title":"Influence of temocillin on colonisation resistance and consequences for therapy","volume":"29","author":"De Vries-Hospers","year":"1985","journal-title":"Drugs"},{"key":"2025120206223948900_dkaf370-B4","doi-asserted-by":"publisher","first-page":"e0248177","DOI":"10.1371\/journal.pone.0248177","article-title":"Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum \u03b2-lactamase producing Escherichia coli in a mouse model","volume":"16","author":"Chenouard","year":"2021","journal-title":"PLoS One"},{"key":"2025120206223948900_dkaf370-B5","doi-asserted-by":"publisher","first-page":"106361","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206223948900_dkaf370-B6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/jac\/dkaa486","article-title":"Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study","volume":"76","author":"Alexandre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223948900_dkaf370-B7","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223948900_dkaf370-B8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","article-title":"The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden","volume":"22","author":"Edlund","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025120206223948900_dkaf370-B9","author":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"2025120206223948900_dkaf370-B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025120206223948900_dkaf370-B11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025120206223948900_dkaf370-B12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"key":"2025120206223948900_dkaf370-B13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/pathogens11030356","article-title":"Antimicrobial resistance in Enterobacterales recovered from urinary tract infections in France","volume":"11","author":"Farfour","year":"2022","journal-title":"Pathogens"},{"key":"2025120206223948900_dkaf370-B14","first-page":"46","volume-title":"CA-SFM\/EUCAST","author":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","year":"2024"},{"key":"2025120206223948900_dkaf370-B15","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025120206223948900_dkaf370-B16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1469-0691.2007.01846.x","article-title":"Phenotypic detection of extended-spectrum \u03b2-lactamase production in Enterobacteriaceae: review and bench guide","volume":"14","author":"Drieux","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2025120206223948900_dkaf370-B17"},{"key":"2025120206223948900_dkaf370-B18","doi-asserted-by":"publisher","first-page":"dlab005","DOI":"10.1093\/jacamr\/dlab005","article-title":"Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis","volume":"3","author":"Heard","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206223948900_dkaf370-B19","doi-asserted-by":"publisher","first-page":"dlac086","DOI":"10.1093\/jacamr\/dlac086","article-title":"Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study","volume":"4","author":"Oosterbos","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206223948900_dkaf370-B20","doi-asserted-by":"publisher","first-page":"dlac132","DOI":"10.1093\/jacamr\/dlac132","article-title":"Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study","volume":"5","author":"Dinh","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206223948900_dkaf370-B21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/jac\/dkae053","article-title":"Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed\/non-exposed study","volume":"79","author":"Bayart","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223948900_dkaf370-B22","doi-asserted-by":"publisher","first-page":"e049481","DOI":"10.1136\/bmjopen-2021-049481","article-title":"Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTART\u00c9): protocol for a randomised, pragmatic trial","volume":"11","author":"Mar\u00edn-Cand\u00f3n","year":"2021","journal-title":"BMJ Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3329\/64432795\/dkaf370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3329\/64432795\/dkaf370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:43Z","timestamp":1764674563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3329\/8268472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf370","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,30]]}}}